Cointime

Gritstone bio

company

About

Gritstone bio develops immunotherapies for cancers and infectious diseases.

  • 101 - 250

Highlights

Total Funding Amount
$400M
Funding Rounds
4
Investors
3

Details

Last Funding Type
Post-IPO Debt
Last Funding Money Raised
$80M
Industries
Biotechnology,Health Care,Therapeutics,Wellness
Founded date
Jan 1, 2015
Number Of Employee
101 - 250
Operating Status
Active

Gritstone Oncology is a clinical-stage biotech company developing tumor-specific cancer immunotherapies to fight multiple cancer types. Its approach seeks to generate a therapeutic immune response by leveraging insights into the immune system’s ability to recognize and destroy tumor cells by targeting tumor-specific neoantigens.

Gritstone Oncology is headquartered in Emeryville, California, with key functions located in Cambridge, Massachusetts, and Pleasanton, California. It was founded in August 2015 and is listed on the Nasdaq Global Select Market under the ticker symbol GRTS.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
4
$400M
Gritstone bio has raised a total of $400M in funding over 2 rounds. Their latest funding was raised on Jul 22, 2022 from a Post-IPO Debt round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Jul 22, 2022 Post-IPO Debt $80M 1 — — Detail
Dec 28, 2020 Post-IPO Equity $125M 1 — — Detail
Sep 7, 2017 Series B $93M 2 Lilly Asia Ventures — Detail
Oct 20, 2015 Series A $102M 1 Versant Ventures — Detail

Investors

Number of Lead Investors
Number of Investors
2
3
Gritstone bio is funded by 3 investors. Lilly Asia Ventures and Hercules Capital are the most recent investors.
Investor Name Lead Investor Funding Round
Lilly Asia Ventures Yes Series B
Hercules Capital — Post-IPO Debt
Versant Ventures — Post-IPO Equity
Cointime
Chủ Đề
Công Ty